Ertumaxomab: Difference between revisions

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

@@ Line 1: / Line 1: @@
+{{Short description|Monoclonal antibody}}
 {{Drugbox
 | Verifiedfields = changed
-| verifiedrevid = 447726538
+| verifiedrevid = 457120720
+<!-- Monoclonal antibody data -->
-<!--Monoclonal antibody data-->
 | type = mab
 | mab_type = 3funct
 | source = axo
 | target = [[HER2/neu]], [[CD3 receptor|CD3]]
+<!-- Clinical data -->
+| tradename = Rexomun
-<!--Clinical data-->
-| tradename =
 | pregnancy_AU =
 | pregnancy_US =
@@ Line 20: / Line 19: @@
 | legal_status =
 | routes_of_administration =
+<!-- Pharmacokinetic data -->
-<!--Pharmacokinetic data-->
 | bioavailability =
 | protein_bound =
@@ Line 27: / Line 25: @@
 | elimination_half-life =
 | excretion =
+<!-- Identifiers -->
+| CAS_number_Ref = {{cascite|changed|??}}
-<!--Identifiers-->
+| CAS_number = 509077-99-0
-| CAS_number_Ref = {{cascite|correct|??}}
+| UNII_Ref          = {{fdacite|correct|FDA}}
-| CAS_number = <!-- blanked - oldvalue: 509077-99-0 -->
+| UNII              = L5L45YGP1O
 | ATC_prefix = none
 | ATC_suffix =
@@ Line 37: / Line 36: @@
 | DrugBank =
 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
-| ChemSpiderID = NA
+| ChemSpiderID = none
+<!-- Chemical data -->
-<!--Chemical data-->
 | chemical_formula =
 | molecular_weight =
 }}
-'''Ertumaxomab''' (trade name '''Rexomun''') is a [[rat]]-[[mouse|murine]] hybrid [[monoclonal antibody]] designed to treat some types of [[cancer]]. {{as of|September 2009}}, a Phase II [[clinical trial]] evaluating the treatment of [[breast cancer]] is recruiting participants.<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00522457 ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy]</ref>
+'''Ertumaxomab''' (trade name '''Rexomun''') is a [[rat]]-[[mouse|murine]] hybrid [[monoclonal antibody]] designed to treat some types of [[cancer]].
+It is a [[trifunctional antibody]] which works by linking [[T-lymphocyte]]s and [[macrophage]]s to the [[cancer cell]]s.<ref>[http://www.fresenius.se/internet/fag/com/faginpub.nsf/Content/P-Info2004_01_15 Fresenius ]</ref>
+Phase II [[clinical trial]] evaluating the treatment of [[breast cancer]] was terminated due to change in [[Fresenius (company)|Fresenius]]' development plans.<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00522457 ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy]</ref> (So they could concentrate on their other product [[catumaxomab]] (trade name Removab).<ref>{{Cite web |url=https://www.fresenius.com/media/gb_englisch_IFRS_2009.pdf |title=2009 Consolidated Financial Statements and Management Report of Fresenius SE |access-date=2016-03-20 |archive-date=2016-03-31 |archive-url=https://web.archive.org/web/20160331111654/https://www.fresenius.com/media/gb_englisch_IFRS_2009.pdf |url-status=dead }}</ref>{{rp|35}})
-It is a so-called [[trifunctional antibody]] which works by linking [[T-lymphocyte]]s and [[macrophage]]s to the [[cancer cell]]s.<ref>[http://www.fresenius.se/internet/fag/com/faginpub.nsf/Content/P-Info2004_01_15 Fresenius ]</ref>
 ==References==
-{{reflist}}
+{{Reflist|2}}
 {{Monoclonals for tumors}}
+{{Growth factor receptor modulators}}
 [[Category:Monoclonal antibodies for tumors]]
+[[Category:Immunology]]
+[[Category:Abandoned drugs]]
 {{monoclonal-antibody-stub}}
 {{antineoplastic-drug-stub}}
-[[it:Ertumaxomab]]